# Zohydro on The No Agenda Show Zohydro comes up in 6 chapters across 3 episodes of The No Agenda Show, from March 2014 to April 2014. - **Chapters:** 6 - **Episodes:** 3 - **Discussed:** March 2014 – April 2014 - **Related topics:** [Fda](https://search.noagendashow.net/topic/fda.md), [Vicodin](https://search.noagendashow.net/topic/vicodin.md), [Addiction](https://search.noagendashow.net/topic/addiction.md), [Forbes](https://search.noagendashow.net/topic/forbes.md), [Abc News](https://search.noagendashow.net/topic/abc-news.md), [Huawei](https://search.noagendashow.net/topic/huawei.md), [Marketing](https://search.noagendashow.net/topic/marketing.md), [Native Advertising](https://search.noagendashow.net/topic/native-advertising.md), [Npr](https://search.noagendashow.net/topic/npr.md), [Opioid](https://search.noagendashow.net/topic/opioid.md) ## Chapters 1–6 of 6 ### Zohydro FDA Approval and Reverse Native Advertising - **Episode:** [611: Let's Get Social!](https://search.noagendashow.net/episode/611-let-s-get-social.md) - **Published:** 2014-04-24 - **Time:** 3:33:26–3:40:00 - **Transcript:** https://search.noagendashow.net/episode/611-let-s-get-social/chapter/zohydro-fda-approval-and-reverse-native-advertising.md The FDA has approved Zohydro, a potent new painkiller that experts warn could be lethal in small doses. Adam Curry presents a theory of "reverse native advertising," suggesting that pharmaceutical companies might pay for news coverage highlighting a drug's danger to ensure it remains a controlled, high-value product on the market. Keywords: [zohydro](https://search.noagendashow.net/topic/zohydro.md), [fda](https://search.noagendashow.net/topic/fda.md), [vicodin](https://search.noagendashow.net/topic/vicodin.md), [richard besser](https://search.noagendashow.net/topic/richard-besser.md), [abc news](https://search.noagendashow.net/topic/abc-news.md), [pharmaceutical marketing](https://search.noagendashow.net/topic/pharmaceutical-marketing.md) ### Show 600 Preparation, Zohydro Drug Approval - **Episode:** [597: Prison Prep](https://search.noagendashow.net/episode/597-prison-prep.md) - **Published:** 2014-03-06 - **Time:** 2:31:22–2:32:46 - **Transcript:** https://search.noagendashow.net/episode/597-prison-prep/chapter/show-600-preparation-zohydro-drug-approval.md As they approach their 600th episode, the hosts begin discussing Zohydro, a powerful new painkiller approved by the FDA. They note the media coverage of the drug's potency and the public health concerns surrounding its release. Keywords: [show 600](https://search.noagendashow.net/topic/show-600.md), [zohydro](https://search.noagendashow.net/topic/zohydro.md), [fda](https://search.noagendashow.net/topic/fda.md), painkillers, [vicodin](https://search.noagendashow.net/topic/vicodin.md), [oxycontin](https://search.noagendashow.net/topic/oxycontin.md) ### Zohydro Media Coverage, Opioid Epidemic - **Episode:** [597: Prison Prep](https://search.noagendashow.net/episode/597-prison-prep.md) - **Published:** 2014-03-06 - **Time:** 2:32:48–2:36:19 - **Transcript:** https://search.noagendashow.net/episode/597-prison-prep/chapter/zohydro-media-coverage-opioid-epidemic.md NPR reports on the controversy surrounding the FDA's approval of Zohydro, which is significantly more powerful than Vicodin. Public health advocates are urging the FDA to withdraw approval, citing the ongoing epidemic of opioid addiction and overdose deaths. Keywords: [zohydro](https://search.noagendashow.net/topic/zohydro.md), [npr](https://search.noagendashow.net/topic/npr.md), [fda](https://search.noagendashow.net/topic/fda.md), [opioid](https://search.noagendashow.net/topic/opioid.md), [addiction](https://search.noagendashow.net/topic/addiction.md), [vicodin](https://search.noagendashow.net/topic/vicodin.md) ### Zohydro Marketing and Abuse, Crushable Pills - **Episode:** [597: Prison Prep](https://search.noagendashow.net/episode/597-prison-prep.md) - **Published:** 2014-03-06 - **Time:** 2:36:20–2:40:08 - **Transcript:** https://search.noagendashow.net/episode/597-prison-prep/chapter/zohydro-marketing-and-abuse-crushable-pills.md The hosts analyze the marketing of Zohydro, focusing on the fact that the pill is "crushable," making it easier to abuse by snorting. They suggest the drug company, Zogenics, is benefiting from the media attention while claiming to monitor for abuse. Keywords: [zohydro](https://search.noagendashow.net/topic/zohydro.md), zogenics, [marketing](https://search.noagendashow.net/topic/marketing.md), crushable, [addiction](https://search.noagendashow.net/topic/addiction.md), [webmd](https://search.noagendashow.net/topic/webmd.md) ### Zohydro ER FDA Approval, Native Advertising - **Episode:** [596: Undesirable Nudity](https://search.noagendashow.net/episode/596-undesirable-nudity.md) - **Published:** 2014-03-06 - **Time:** 35:35–38:44 - **Transcript:** https://search.noagendashow.net/episode/596-undesirable-nudity/chapter/zohydro-er-fda-approval-native-advertising.md The FDA approved Zohydro ER, a high-dose pure hydrocodone pill, despite an 11-2 vote against it by an advisory committee. Media coverage of the drug's launch is criticized as "native advertising" that highlights the drug's potency (10 times that of Vicodin) while ostensibly warning of its dangers. The drug is described as "heroin in a pill" and is set to hit the market in March 2014. Keywords: zohydro er, [fda](https://search.noagendashow.net/topic/fda.md), hydrocodone, [opioid crisis](https://search.noagendashow.net/topic/opioid-crisis.md), [forbes](https://search.noagendashow.net/topic/forbes.md) ### Forbes Native Advertising, Zohydro Ad Placement - **Episode:** [596: Undesirable Nudity](https://search.noagendashow.net/episode/596-undesirable-nudity.md) - **Published:** 2014-03-06 - **Time:** 38:44–43:56 - **Transcript:** https://search.noagendashow.net/episode/596-undesirable-nudity/chapter/forbes-native-advertising-zohydro-ad-placement.md An article in Forbes by contributor Melanie Haken is analyzed for its use of native advertising, featuring a large ad for Zohydro ER embedded within a piece about its dangers. The text describes the "high" of the drug lasting 12 hours, which is viewed as a promotional tactic disguised as a health warning. Similar "fawning" coverage of tech companies like Huawei is cited as evidence of a new, paid-for writing style in mainstream business journalism. Keywords: [forbes](https://search.noagendashow.net/topic/forbes.md), melanie haken, [native advertising](https://search.noagendashow.net/topic/native-advertising.md), [zohydro](https://search.noagendashow.net/topic/zohydro.md), [huawei](https://search.noagendashow.net/topic/huawei.md) --- This is the markdown version of a page on The No Agenda Show for AI agents. Every public page on this site has one: add `.md` to its URL, or request it with `Accept: text/markdown`. - [Site index for agents (llms.txt)](https://search.noagendashow.net/llms.txt) - [Home](https://search.noagendashow.net/index.md) - [Search transcripts](https://search.noagendashow.net/search.md) - [All episodes](https://search.noagendashow.net/episodes.md) - [Topics](https://search.noagendashow.net/topics.md) - [People](https://search.noagendashow.net/people.md)